Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study

被引：0
|
作者：
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China
[3] Gansu Prov Hosp, Dept Hematol, Gansu, Peoples R China
[4] Hebei Med Univ, Dept Hematol, Hosp 1, Shijiazhuang, Peoples R China
[5] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Jilin Univ, Dept Hematol, Affiliated Hosp 1, Changchun, Peoples R China
[7] Qingdao Univ, Affiliated Hosp, Dept Hematol, Med Coll, Qingdao, Peoples R China
[8] First Affiliated Hosp, Dept Hematol, Nanyang Med Coll, Nanyang, Peoples R China
[9] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China
[10] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[11] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[12] Henan Univ Sci & Technol, Dept Hematol, Affiliated Hosp 1, Luoyang, Peoples R China
[13] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[14] Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Sch Med, Hangzhou, Peoples R China
[15] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM JUMP: AN OPEN LABEL, MULTICENTER, SINGLE-ARM, EXPANDED-ACCESS STUDY
    Passamonti, F.
    Zaritskey, A.
    Giraldo, P.
    Liberati, A. M.
    Niederwieser, D.
    Palandri, F.
    Raanani, P.
    Griesshammer, M.
    Vannucchi, A. M.
    Al-Ali, H. K.
    Gupta, V.
    Martino, B.
    Foltz, L.
    Ronco, J. Perez
    Ghosh, J.
    Bouard, C.
    Tavares, R.
    HAEMATOLOGICA, 2016, 101 : 93 - 93
  • [32] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
    Samuel, David
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Bahlis, Nizar J.
    Alsina, Melissa
    Chanan-Khan, Asher A.
    Somlo, George
    Buadi, Francis
    Reu, Frederic J.
    Zonder, Jeffrey A.
    Song, Kevin
    Stadtmauer, Edward
    Wong, Alvin F.
    Vallone, Marcy
    Chang, Yu-Lin
    Kauffman, Michael
    Orlowski, Robert Z.
    Stewart, A. Keith
    Singhal, Seema B.
    BLOOD, 2010, 116 (21) : 433 - 433
  • [33] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [34] A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China
    Zheng, Zhong
    Zhang, Huilai
    Wang, Jingwen
    Zhou, Keshu
    Zhang, Li
    Zhou, Hui
    Zhang, Qingyuan
    Zhao, Weili
    BLOOD, 2021, 138
  • [35] QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens
    Moore, Kathleen N.
    Secord, Angeles Alvarez
    Geller, Melissa Ann
    Miller, David S.
    Cloven, Noelle Gillette
    Fleming, Gini F.
    Hendrickson, Andrea Elisabeth Wahner
    Azodi, Masoud
    DiSilvestro, Paul
    Oza, Amit M.
    Cristea, Mihaela C.
    Berek, Jonathan S.
    Chan, John K.
    Clark, Romnee
    Matulonis, Ursula A.
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies
    Zheng Weiwei
    Zhou Hui
    Xi Zhang
    Jing Hongmei
    Zhou Dongmei
    Zhou Fang
    Gao Li
    Wan Wei
    Song Yaobo
    Yan, Haung
    Xu Linfeng
    Hu Yonghan
    Le Meijie
    Qi Junyuan
    Qiu, Lugui
    BLOOD, 2022, 140 : 9353 - 9355
  • [37] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 309 - 317
  • [38] A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)
    Berdeja, Jesus
    Savona, Michael
    Mace, Joseph R.
    Hart, Lowell
    Essell, James
    Owera, Rami
    Arrowsmith, Edward
    Flinn, Ian
    BLOOD, 2013, 122 (21)
  • [39] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Rogerio, Jaqueline Willemann
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Rod
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345